Results 231 to 240 of about 271,361 (298)

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

A prospective exploration of the association between acute stress disorder and posttraumatic stress disorder in reaction to war: disengaged coping as a moderator. [PDF]

Eur J Psychotraumatol
Baziliansky S, Sowan W.
europepmc   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Inflammatory biomarker outcomes associated with MDMA-assisted therapy: an open-label exploratory study. [PDF]

Front Neurosci
Kachmarik JE, Loftis JM, Stauffer CS.
europepmc   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Residential Therapy With Navigated Transcranial Magnetic Stimulation for Combat-Related PTSD: A Randomized Clinical Trial.

JAMA Netw Open
Fox PT, Salinas FS, Roache JD, Quinones M, Vaughan PW, Franklin C, Straud CL, Price L, Unzueta-Hernandez M, Woolsey MK, Chavez AM, Hoselton DA, Brundige AR, Litz BT, Young-McCaughan S, Keane TM, Peterson AL, Consortium to Alleviate PTSD.   +17 more
europepmc   +1 more source

A Cross-Sectional Analysis of Psychological and Dermatologic Manifestations Post-February 6 Earthquakes in Dermatology Patients. [PDF]

Ann Dermatol
Gençoğlu Ş, Cansel N.
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Post-Traumatic Stress Disorder in Residential Care After an Earthquake: A Follow-Up Study. [PDF]

Noro Psikiyatr Ars
Erbay MF, Karayağmurlu A, Karan P, Soylu N.   +3 more
europepmc   +1 more source